Comment
Several portfolio companies are approaching crucial...
The year began with us changing the company's name to KDventures – a name change that marks a new start...
Publicerad: 30 April, 2026
News
Category
Laddar...
Sorry, nothing matches this category.
Comment
Strong interest in Modus TO programme
Modus Therapeutics strengthens its financial position and focuses on the Phase IIa study with sevuparin....
Publicerad: 28 April, 2026
Don’t miss the annual report for 2025
2025 was filled with progress in clinical development and strategic collaborations across our portfolio...
Publicerad: 27 April, 2026
Viktor Drvota at Redeye
Watch KDventure's CEO Victor Drvota present the company's investment strategy and answer questions.
Publicerad: 5 March, 2026